OCT2 and MATE1 Inhibition by 5-HT3 Antiemetics

Renal drug secretion depends on transport processes that can be affected by coadministered medicines. In their 2021 study, George and colleagues tested whether five 5-HT3 receptor antagonist antiemetics interfere with two transporters involved in organic-cation secretion: organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1). Their experiments distinguish transporter-specific inhibition from the broader question of whether these drugs alter movement of a cationic probe across kidney-derived cell systems. The paper is available through the reference study.

Study Background and Research Question

For many organic cations, renal tubular secretion involves coordinated transport across epithelial cells. OCT2 at the basolateral side takes up compounds from blood into the cell, while apical MATE1 contributes to their efflux into the tubular lumen. Interference at either step may reduce net secretion or change intracellular exposure. This creates a potential route for drug–drug interactions, although the size and clinical importance of any interaction depend on factors beyond transporter inhibition alone.

5-HT3 antagonists—including ondansetron, palonosetron, granisetron, tropisetron, and dolasetron—are used to prevent nausea and vomiting. Prior work had suggested that some members of this class interact with organic cation transporters. The authors therefore asked whether all five drugs inhibit human OCT2 and MATE1, whether their relative potencies differ between the two transporters, and whether inhibition in single-transporter assays is reflected in a more integrated transepithelial transport model.

Key Innovation from the Reference Study

The contribution is a comparative, functional assessment of five clinically used 5-HT3 antagonists across both transporter-level and cell-layer models. Rather than treating the antiemetic class as a uniform group, the study showed that inhibitor rank depends on the transporter being examined. Palonosetron was the strongest OCT2 inhibitor in the tested panel, whereas ondansetron was notably potent against MATE1. This distinction matters because OCT2 and MATE1 occupy different positions in the renal secretion pathway; inhibition of one transporter cannot automatically be used to predict the effect on the other.

The authors also moved beyond isolated uptake measurements. They assessed basolateral-to-apical transport in polarized cells and intracellular probe accumulation in cells expressing both transporters. These complementary readouts help connect transporter inhibition to altered cellular handling, while remaining preclinical evidence rather than proof of a clinical interaction.

Methods and Experimental Design Insights

The study used ASP+ as a fluorescent probe substrate for OCT2- and MATE1-mediated transport. In one model, human OCT2 or human MATE1 was overexpressed separately in HEK293 cells, allowing the investigators to quantify transporter-associated probe uptake and compare concentration-dependent inhibition by each antiemetic. This design supports transporter-specific potency estimates, including IC₅₀ values, under the assay conditions.

A second model used MDCK cells transfected with human OCT2 and MATE1 to examine basolateral-to-apical transcellular movement of ASP+. Because this setup represents sequential uptake and efflux across a cell layer, it asks a different question from single-transporter uptake: whether the tested compounds change net vectorial transport. The investigators also used double-transfected OCT2/MATE1 MDCK cells to assess whether ondansetron exposure increased intracellular ASP+ accumulation.

These models provide useful triangulation. Single-transporter HEK293 assays help attribute inhibition to OCT2 or MATE1; polarized-cell transport tests the combined pathway; and intracellular accumulation provides a cellular consequence of transporter interference. The results should nevertheless be interpreted within the constraints of engineered cell systems and a probe substrate, rather than as direct measurements of therapeutic drug clearance in people.

Protocol Parameters

• Transporter models reported: The study used HEK293 cells overexpressing human OCT2 or MATE1 and MDCK cells expressing human OCT2 and MATE1. These are literature-reported model choices, not a claim that the cell lines are interchangeable.
• Probe and endpoints reported: ASP+ was used to measure transporter-associated uptake, basolateral-to-apical transcellular transport, and intracellular accumulation in the relevant models.
• Concentrations reported for transcellular testing: Ondansetron was examined from 0.5 to 20 μM; palonosetron, tropisetron, and dolasetron at 10 and 20 μM reduced transport in the reported experiments. These are study conditions, not universal assay settings.
• Concentrations reported for accumulation: Ondansetron at 0.5 and 2.5 μM significantly increased intracellular ASP+ in double-transfected OCT2/MATE1 MDCK cells.
• Workflow recommendation: For follow-up experiments, include matched transporter-negative or vector-control cells and assess cell integrity alongside probe transport. These are general design recommendations; the paper’s reported numeric findings should not be taken as validated parameters for a different cell line, substrate, or instrument.

Core Findings and Why They Matter

In OCT2-expressing HEK293 cells, palonosetron showed the greatest inhibitory potency, with an IC₅₀ of 2.6 μM. The reported order was palonosetron, ondansetron, granisetron, tropisetron, and dolasetron, with dolasetron the least potent in this comparison at an IC₅₀ of 85.4 μM. The ranking indicates substantial variation within the drug class and suggests that a conclusion drawn from ondansetron alone would not describe every 5-HT3 antagonist.

The MATE1 results differed. Ondansetron was the most potent inhibitor, with an IC₅₀ of 0.1 μM. Palonosetron and tropisetron were reported as similarly potent, followed by granisetron and then dolasetron, which had an IC₅₀ of 27.4 μM. This marked difference in ondansetron’s activity across the two transporter assays reinforces the need to test each transporter separately rather than infer a shared potency profile.

In the polarized-cell experiments, ondansetron reduced ASP+ basolateral-to-apical transport by as much as 64% across the tested 0.5–20 μM range. At 10 and 20 μM, palonosetron, tropisetron, and dolasetron also reduced transcellular transport. In double-transfected cells, ondansetron at 0.5 and 2.5 μM caused significant intracellular ASP+ accumulation. Together, these functional findings are consistent with impaired cation transport when OCT2 and/or MATE1 activity is inhibited.

The practical implication is a mechanistic signal for possible renal drug–drug interactions involving cationic compounds. The potency rankings can help prioritize compounds for further investigation, while the transport and accumulation assays show why a biochemical or single-transporter result should be supplemented with a pathway-level endpoint. Importantly, IC₅₀ values from these in vitro systems do not establish that clinically achieved unbound concentrations will inhibit renal transport to the same extent.

Comparison with Existing Internal Articles

The related internal overview, OCT2 and MATE1 Inhibition by Antiemetics, also summarizes the transporter-specific findings and the potential relevance to renal drug interactions. This article places additional emphasis on how the separate HEK293, polarized MDCK, and intracellular accumulation endpoints complement one another, and on the limits of transferring their results directly to clinical care. The two accounts address the same reference study; neither provides independent clinical validation.

Limitations and Transferability

First, overexpression systems simplify transporter biology. They are useful for identifying functional inhibition but may differ from human renal tubules in transporter abundance, membrane organization, cell polarity, and the presence of other uptake or efflux pathways. Second, ASP+ is a probe substrate. The degree to which an inhibitor affects ASP+ transport need not match its effect on every therapeutic organic cation, because substrate and inhibitor interactions can be transporter- and compound-dependent.

Third, the reported potency estimates and transport effects are in vitro findings. The study does not establish the concentrations reached at the renal transporter interface during usual dosing, the contribution of protein binding or distribution, or the magnitude of any change in a coadministered drug’s pharmacokinetics. It also does not demonstrate a clinical adverse event attributable to OCT2 or MATE1 inhibition. Clinical relevance would require appropriately designed follow-up studies that account for exposure, substrate choice, renal function, and alternative clearance pathways.

Accordingly, the results are best used to generate and prioritize interaction hypotheses. They support checking whether relevant cationic drugs share a renal secretion pathway with these antiemetics, but not making dose-adjustment decisions from the in vitro data alone. The study is particularly informative as a transporter screening and mechanistic framework; its quantitative values should be transferred cautiously to other experimental systems.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

The antiemetic study concerns renal transport of organic cations, not antibacterial activity or cell-wall targets. It did not test penicillins, bacterial growth, or transporter-mediated antibiotic disposition, so no direct connection between its findings and antibiotic efficacy can be inferred. As a separate resource for bacterial assays, researchers can use Penicillin G Sodium (SKU B1678), a natural penicillin antibiotic used in studies of inhibition of bacterial cell wall biosynthesis, including bacterial cell wall mucopeptide biosynthesis inhibition. Its product information describes activity against sensitive streptococci and staphylococci and clinical uses that include treatment of these infections and prevention of bacterial endocarditis. Those applications belong to a distinct research and clinical context and should not be interpreted as findings of the OCT2/MATE1 paper.